Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...

Counterpart Health, MEDITECH, and Suki are using Vertex AI Search for healthcare ... where nearly 90% of healthcare data is in image form – such as x-rays, scans, or photos.

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.11% to $479.79 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.59% ...

Vertex's total revenues for Q4 2024 were $ ... under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, to be filed with the ...